JP2025514180A - 強化された肝臓及び腎臓特異的標的化のための遺伝子配列－炭水化物コンジュゲート - Google Patents

強化された肝臓及び腎臓特異的標的化のための遺伝子配列－炭水化物コンジュゲート Download PDF

Info

Publication number
JP2025514180A
JP2025514180A JP2024563257A JP2024563257A JP2025514180A JP 2025514180 A JP2025514180 A JP 2025514180A JP 2024563257 A JP2024563257 A JP 2024563257A JP 2024563257 A JP2024563257 A JP 2024563257A JP 2025514180 A JP2025514180 A JP 2025514180A
Authority
JP
Japan
Prior art keywords
conjugate
mir
pna
carbohydrate
gene sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024563257A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025514180A5 (enExample
Inventor
ラマン バハル
ヴィカス クマール
アニケト ワハネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Connecticut
Original Assignee
University of Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Connecticut filed Critical University of Connecticut
Publication of JP2025514180A publication Critical patent/JP2025514180A/ja
Publication of JP2025514180A5 publication Critical patent/JP2025514180A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2024563257A 2022-04-26 2023-04-26 強化された肝臓及び腎臓特異的標的化のための遺伝子配列－炭水化物コンジュゲート Pending JP2025514180A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263335174P 2022-04-26 2022-04-26
US63/335,174 2022-04-26
PCT/US2023/019940 WO2023212027A2 (en) 2022-04-26 2023-04-26 Genetic sequence-carbohydrate conjugates for enhanced liver- and kidney-specific targeting

Publications (2)

Publication Number Publication Date
JP2025514180A true JP2025514180A (ja) 2025-05-02
JP2025514180A5 JP2025514180A5 (enExample) 2026-05-08

Family

ID=88519558

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563257A Pending JP2025514180A (ja) 2022-04-26 2023-04-26 強化された肝臓及び腎臓特異的標的化のための遺伝子配列－炭水化物コンジュゲート

Country Status (6)

Country Link
US (1) US20250346895A1 (enExample)
EP (1) EP4514970A2 (enExample)
JP (1) JP2025514180A (enExample)
CN (1) CN119213006A (enExample)
CA (1) CA3256515A1 (enExample)
WO (1) WO2023212027A2 (enExample)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6746868B1 (en) * 1997-09-18 2004-06-08 Isis Pharmaceuticals, Inc. Chemical modification of DNA using peptide nucleic acid conjugates
NZ528966A (en) * 2003-10-17 2006-11-30 Otago Innovation Ltd Peptide nucleic acid conjugates and uses thereof
EP2229186A2 (en) * 2007-12-04 2010-09-22 Alnylam Pharmaceuticals Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
US11833254B2 (en) * 2020-05-27 2023-12-05 University Of Connecticut Discoidal nano universal platform for efficient delivery of PNAs

Also Published As

Publication number Publication date
US20250346895A1 (en) 2025-11-13
WO2023212027A3 (en) 2023-12-07
CA3256515A1 (en) 2023-11-02
WO2023212027A2 (en) 2023-11-02
EP4514970A2 (en) 2025-03-05
CN119213006A (zh) 2024-12-27

Similar Documents

Publication Publication Date Title
JP6715325B2 (ja) ｓｉＲＮＡ、ｓｉＲＮＡを含む医薬組成物及び結合体、並びにそれらの応用
JP7438103B2 (ja) アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物
JP5697988B2 (ja) 干渉ｒｎａを使用したポロ様キナーゼ発現のサイレンシング方法
CA2917320C (en) Respiratory disease-related gene specific sirna, double-helical oligo rna structure containing sirna, composition containing same for preventing or treating respiratory disease
WO2025097633A1 (zh) 靶向调控PCSK9基因表达的siRNA及其应用
JP2022501040A (ja) １７β−ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法
JP2024528634A (ja) 二本鎖オリゴヌクレオチド、二本鎖オリゴヌクレオチドを含む組成物及び複合体並びに調製方法と使用
BR112016000160B1 (pt) estrutura de oligonucleotídeo tipo nanopartícula melhorada tendo alta eficiência e método para a preparação da mesma
CA3242059A1 (en) Nucleic acid, composition and conjugate containing nucleic acid, preparation method thereof and use thereof
CN114716518A (zh) 一种能够抑制pcsk9表达的分子构造及药物组合物
KR20260045699A (ko) AGT 유전자 발현을 표적으로 억제하는 siRNA 및 고혈압 치료에서의 이의 용도
JP7306653B2 (ja) 構造強化されたＳ－ＴｕＤを用いた新規がん治療法
CN119487192A (zh) 小激活核酸分子及其在治疗遗传性血管性水肿中的用途
KR20130068032A (ko) 안정한 안티센스 올리고뉴클레오티드 접합체 및 그 제조방법
US20250346895A1 (en) Genetic sequence-carbohydrate conjugates for enhanced liver- and kidney-specific targeting
TW202444904A (zh) 用於抑制粒線體醯胺肟還原組分1(MARC1)之表現之RNAi藥劑、其醫藥組合物及使用方法
US20260125681A1 (en) DOUBLE-STRANDED RNAi AGENTS FOR TARGETING AND REGULATING HBV GENE EXPRESSION, AND A USE THEREOF
US20240409938A1 (en) Lipophilic sirna conjugates for the treatment of central nervous system diseases
JP7412668B2 (ja) アンチセンスオリゴヌクレオチド複合体
JP7709164B2 (ja) 核酸送達促進剤
WO2018062233A1 (ja) カチオン性脂質としての化合物
Wang Poly (ethylene) Glycol-Based Bottlebrush Polymers as Nanocarriers for Oligonucleotide Therapeutics: Design, Synthesis, and Applications
WO2025091026A1 (en) Therapeutic compositions containing g-clamp pna and uses thereof
WO2026046236A1 (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
HK40124050A (en) Sirna for targeted regulation of hbv gene expression and application thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260424